Browsing Tag
Dallas
68 posts
Texas Instruments (TXN) profit jumps 78% as industrial and AI data-centre demand strengthens
Texas Instruments reported 28% revenue growth and a substantial increase in operating profitability as demand improved across industrial, automotive and data-centre markets. The results suggest that the semiconductor recovery is extending beyond AI accelerators, although high investor expectations and future manufacturing utilisation will influence returns.
Strive closes upsized $630m SATS offering as Bitcoin treasury strategy accelerates
Strive raised $630 million through 15% SATS preferred stock as $ASST climbed. See how the deal could fuel more Bitcoin purchases and reshape risk.
Bovita Health combines colostrum, fiber and Akkermansia. Can its new formula compete in metabolic wellness?
Bovita Health has introduced Colostrum + Metabolic Fiber, combining bovine colostrum, dietary fiber and Akkermansia in a daily supplement positioned around appetite and metabolic wellness. The product enters a growing market for gut-focused formulations, where scientific substantiation and repeat purchases are important competitive factors.
Arrowfly buys Prosper Company as restaurant leadership events become next growth engine
Arrowfly has acquired Prosper Company, adding two restaurant and hospitality leadership events to a portfolio already spanning more than 40 media brands and dozens of annual events as the Mountaingate Capital-backed group continues its buy-and-build strategy.
Tenet just lifted its profit outlook. Why are 1,037 Conifer employees losing their jobs?
Tenet Healthcare-owned Conifer Health Solutions will permanently eliminate 1,037 jobs as its CommonSpirit Health relationship winds down, even as Tenet reports sharply higher profit and raises its 2026 outlook.
Rentokil (LSE: RTO) shares remain near their post-results low as North America turnaround faces a harder test
Rentokil Initial is generating more profit, cash and margin from North America, but investors erased a fifth of its value after management prioritised revenue recovery over its old 2027 margin target. Two weeks later, the shares have barely recovered.
T1 Energy sales hit $250m as $135m solar IP deal raises the stakes for U.S. expansion
T1 Energy posted $250 million in Q2 sales while expanding U.S. solar manufacturing. See why financing and dilution remain key risks.
Zayo and NVIDIA target AI network bottleneck with six new long-haul fibre routes
Zayo is working with NVIDIA to expand long-haul fibre capacity across emerging United States AI corridors, linking the semiconductor company’s accelerated-computing ecosystem with Zayo’s largest network construction programme. The infrastructure opportunity is substantial, but undisclosed commercial terms and long construction cycles leave the financial returns dependent on customer commitments, utilisation and disciplined execution.
Lantern Pharma just separated its AI platform, but will Open Medicine AI unlock real shareholder value?
Lantern Pharma has established Open Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform, moving a previously planned separation into an active corporate structure. The decision could give the artificial intelligence business greater strategic focus and access to specialized funding, but ownership, intellectual property, customer revenue and future listing arrangements will determine whether the move creates measurable value for Lantern Pharma shareholders.
Rentokil Initial (LSE: RTO) falls 20% after retiring US margin target
Rentokil Initial delivered stronger first-half profit and cash flow, but abandoning its 2027 North American margin target reopened doubts about the US$6.7 billion Terminix acquisition.